1	Bruce G. Chapman (State Bar No. 16425	(8)	
2	bchapman@cblh.com Keith D. Fraser (State Bar No. 216279)		
	kfraser@cblh.com CONNOLLY BOVE LODGE & HUTZ	IIP	
3	333 S. Grand Ave., Suite 2300	DDI	
4	Los Angeles, CA 90071 Telephone: (213) 787-2500 Facsimile: (213) 687-0498		
5	Facsimile: (213) 687-0498		
6	Dianne B. Elderkin (admitted pro hac vio	ce)	
7	delderkin@akingump.com Barbara L. Mullin (admitted <i>pro hac vice</i>		
	bmullin@akingump.com Steven D. Maslowski (admitted <i>pro hac</i>		
8	smaslowski@akingump.com		
9	averrecchio@akingump.com		
10			
11	Rubén H. Muñoz (admitted <i>pro hac vice</i>)		
12	rmunoz@akingump.com AKIN GUMP STRAUSS HAUER & FELD LLP		
13	Two Commerce Square, Suite 4100 2001 Market Street		
	Philadelphia, Pennsylvania 19103-7013		
14	Facsimile: (215) 965-1210		
15	Attorneys for Plaintiff and Counter-Defendant CENTOCOR ORTHO BIOTECH, INC. and Third-Party Defendants GLOBAL PHARMACEUTICAL SUPPLY		
16	INC. and Third-Party Defendants GLOB	AL PHARMACEUTICAL SUPPLY CS, LLC and JOM PHARMACEUTICAL	
17	SERVICES, INC.	es, ele and fow i in the cele i lette	
18	IN THE UNITED STATES DISTRICT COURT		
19			
20	CENTOCOR ORTHO BIOTECH,	Case No. CV 08-03573 MRP (CTx)	
21	INC.,	PLAINTIFF'S UNOPPOSED EX	
	Plaintiff,	PARTE APPLICATION TO AMEND THE CASE SCHEDULE	
22	v.		
23	GENENTECH, INC. and CITY OF	Date: TBA Time: TBA	
24	HOPE,	Place: Hon. Mariana Pfaezler, Courtroom 12	
25	Defendants.	Courtioon 12	
26			
27	AND RELATED COUNTER AND THIRD-PARTY ACTIONS.		
28			
ا ا			

I. <u>INTRODUCTION</u>

Pursuant to Local Rule 7-19, Plaintiff Centocor Ortho Biotech, Inc. ("Centocor") hereby applies to the Court *ex parte* for an order amending the case schedule to allow for sufficient time to take discovery in light of witness availability before the current deadline for fact discovery. Specifically, Plaintiff respectfully requests an order extending the deadline for fact discovery until August 13, 2010.

Pursuant to Local Rules 7-19 and 7-19.1, counsel for Plaintiff contacted counsel for Defendants to advise them of the substance of the instant *ex parte* application. Counsel indicated that Defendants would not oppose Plaintiff's *ex parte* application. The contact information for Defendants' counsel City of Hope Medical Center and Genentech, Inc. are as follows:

David I. Gindler
Joseph M. Lipner
Irell & Manella LLP
1800 Avenue of the Stars, Suite 900
Los Angeles, CA 90067-4276
Tel: 310-277-1010
Email: jlipner@irell.com
dgindler@irell.com

Mark A. Pals
Marcus E. Sernel
Kirkland & Ellis LLP
300 North LaSalle Street
Chicago, IL 60654
Tel: 312-861-2000
Email: mpals@kirkland.com
msernel@kirkland.com

Daralyn J. Durie
Ryan Kent
Durie Tangri, LLP
217 Leidesdorff Street
San Francisco, CA 94111
Tel: 415-362-6666
Email: ddurie@durietangri.com
rkent@durietangri.com

On March 11, 16, and 19, 2010, Matthew Pearson, counsel for Centocor, spoke via telephone with Marc Sernel, counsel for defendant Genentech. Mr. Pearson advised Mr. Sernel of, to the extent known, the date, time and substance of the

Application. After such notification, counsel represented that Genentech would not oppose this Application.

On March 19, 2010, Mr. Pearson spoke via electronic mail with David Gindler, counsel for defendant City of Hope. Mr. Pearson advised Mr. Gindler of, to the extent known, the date, time and substance of the Application. After such notification, counsel represented that City of Hope would not oppose this Application.

II. GOOD CAUSE EXISTS TO GRANT PLAINTIFF'S REQUEST FOR CONTINUANCE OF THE CASE SCHEDULE

An extension of the fact discovery deadline, which is currently April 30, 2010, is necessary because there remain numerous depositions to be taken of all parties' witnesses. One of these witnesses is Wendy Lee, who recently had a baby and thus has not been available and is not available for a deposition until the week after the close of fact discovery. Ms. Lee is an attorney who was involved in the prosecution of one of the patents in suit, and she is listed on Genentech's Initial Disclosures as likely having relevant information about that prosecution. Centocor expects her testimony to be highly relevant because the record reflects that she was a prosecuting attorney for Genentech who made statements to the U.S. Patent and Trademark Office that Centocor contends contradict earlier statements made by another Genentech attorney in a European proceeding involving the European counterpart to the Cabilly patent in suit.

Because of Ms. Lee's apparent role in the prosecution of the Cabilly patent family at issue, her deposition may lead to additional depositions of other persons similarly involved. In addition, expert witnesses may be asked to opine on her testimony and any follow-up discovery, and would need a reasonable opportunity to prepare those opinions. Additionally, certain Centocor experts are unavailable for a period of time over the summer months, making an extension of several months reasonably necessary to complete discovery.

1	Centocor therefore respectfully requests an extension of the deadline for fact	
2	discovery in this case through August 13, 2010. The following additional dates are	
3	proposed, corresponding to an August 13, 2010 fact discovery deadline.	
4	Opening expert reports: August 30, 2010	
5	Responsive expert reports: September 20, 2010	
6	Expert discovery completed: October 11, 2010	
7	Summary judgment motions: October 27, 2010	
8	Oppositions to summary judgment: November 11, 2010	
9	Replies in support of summary judgment: November 18, 2010	
10	Summary judgment hearing: December 1, 2010	
11	III. <u>CONCLUSION</u>	
12	For the foregoing reasons, Plaintiff respectfully requests that this Court	
13	continue the dates set forth in the Court's Scheduling Order as requested herein.	
14		
15	DATED: March 22, 2010 Respectfully submitted,	
16	AKIN GUMP STRAUSS HAUER & FELD LLP	
17	By: /s/ Dianne B. Elderkin	
18	Dianne B. Elderkin	
19	and	
20	CONNOLLY BOVE LODGE & HUTZ LLP	
21	By:/s/Bruce G. Chapman	
22	Bruce G. Chapman	
23	Attorneys for Plaintiff and Counter-Defendant Centocor Ortho Biotech, Inc. and Third-Party	
24	Defendants Global Pharmaceutical Supply	
25	Group, LLC, Centocor Biologics, LLC and JOM Pharmaceutical Services, Inc.	
26		
27		
28		
	1	